PMID- 31424641
OWN - NLM
STAT- MEDLINE
DCOM- 20200302
LR  - 20200302
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 24
IP  - 3
DP  - 2019 May-Jun
TI  - Anticancer effects of curzerenone against drug-resistant human lung carcinoma 
      cells are mediated via programmed cell death, loss of mitochondrial membrane 
      potential, ROS, and blocking the ERK/MAPK and NF-kappaB signaling pathway.
PG  - 907-912
AB  - PURPOSE: The main objective of the current study was to examine the anticancer 
      effects of Curzerenone - a naturally occurring sesquiterpene against 
      gemcitabine-resistant lung carcinoma cells. The effects of Curzerenone on 
      mitochondrial-mediated apoptosis, ROS, and ERK/MAPK and NF-kB signalling pathways 
      were also investigated in the present study. METHODS: Cell proliferation was 
      evaluated by MTT assay. Apoptosis was detected by acridine orange (AO)/ethidium 
      bromide (EB) and DAPI staining as well as flow cytometry using annexin V 
      apoptosis assay. The effects on reactive oxygen species (ROS) as well as 
      mitochondrial membrane potential (MMP) were examined by flow cytometry. Protein 
      expression was examined by western blotting. RESULTS: It was found that 
      Curzerenone induced potent antiproliferative effects against the 
      gemcitabine-resistant lung cancer cells and exhibited an IC50 of 24 microM. The 
      anticancer effects of curzerenone were due to the induction of apoptosis which 
      was also associated with alteration of apoptosis-related proteins (Bax,Bcl-2). 
      Curzerenone also caused ROS-mediated alterations in the MMP. Curzerenone induced 
      cell death in gemcitabine-resistant lung cancer cells by activating p38 MAPK/ERK 
      signalling pathway while NF-kB pathway was inhibited in a dose-dependent manner. 
      CONCLUSIONS: In conclusion, the current results strongly indicate that 
      Curzerenone may prove a potential anticancer drug candidate against 
      drug-resistant lung cancer.
FAU - Zheng, Tingting
AU  - Zheng T
AD  - Department of Ultrasound, Peking University Shenzhen Hospital, Shenzhen, 
      Guangdong, 518036, China.
FAU - Chen, Haitao Xiao Yuehong Shen Xue Zhang Kunkun Jiang Li Liu Xiaohe Bai Jiao Peng 
      Yun
AU  - Chen HXYSXZKJLLXBJPY
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Extracts)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Terpenes)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - MAP Kinase Signaling System/*drug effects
MH  - Membrane Potential, Mitochondrial/*drug effects
MH  - NF-kappa B/*drug effects
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - Reactive Oxygen Species
MH  - Signal Transduction
MH  - Terpenes/pharmacology/*therapeutic use
EDAT- 2019/08/20 06:00
MHDA- 2020/03/03 06:00
CRDT- 2019/08/20 06:00
PHST- 2019/08/20 06:00 [entrez]
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2020/03/03 06:00 [medline]
PST - ppublish
SO  - J BUON. 2019 May-Jun;24(3):907-912.